0

<< Acute Kidney Injury in Pediatric Patients: Diagnosis and Management in the Emergency Department (Pharmacology CME)

Controversies and Cutting Edge

Biomarkers for Diagnosis of Acute Kidney Injury

Much of the current clinical investigation regarding AKI has focused on the use of novel biomarkers for the prompt diagnosis of AKI. Biomarkers under investigation include neutrophil gelatinase associated lipocalin (NGAL), interleukin-18 (IL-18), kidney injury molecule-1 (KIM-1), cystatin C (CysC), tissue inhibitor of metalloproteinases-2 (TIMP-2), insulin-like growth factor-binding protein 7 (IGFBP7), and liver fatty acid-binding protein (L-FABP).64 The promise in these biomarkers is that they may identify AKI earlier in the course of renal injury than SCr elevation, allowing more timely diagnosis and intervention. Urinary biomarkers have shown limited ability to detect pAKI at the pRIFLE Risk stage, but greater promise in identifying patients at the pRIFLE Injury stage in the emergency setting.91

To continue reading, please log in or purchase access.

Already purchased this course?
Log in to read.
Purchase a subscription

Price: $449/year

140+ Credits!

Purchase Issue & CME Test

Price: $49

+4 Credits!

Money-back Guarantee
Get Quick-Read Evidence-Based Updates
Enter your email to get free evidence-based content delivered to your inbox once per month.
Please provide a valid email address.